Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Maternal Inclusion Criteria:~* HIV infection~* Greater than or equal to 18 years of age~* Able and willing to provide signed informed consent for herself and her infant~Maternal Exclusion Criteria:~* Prior participation in any HIV-1 vaccine trial~* Receipt of any other active or passive HIV immunotherapy or investigational product during this pregnancy. (Note that administration of Food and Drug Administration \[FDA\]-approved antiretroviral (ARV) drugs when used to treat disease or prevent mother-to-child transmission were not considered investigational.)~* Documented or suspected serious medical illness or immediate life-threatening condition (other than HIV infection) in the mother that may have interfered with the ability to complete study requirements, as judged by the examining clinician~Infant Inclusion Criteria:~* Born to an HIV-1-infected woman who met all maternal inclusion/exclusion criteria listed above~* Gestational age, by best obstetrical, ultrasound, or infant exam, greater than or equal to 36 weeks~* Birth weight greater than or equal to 2.0 kg~* Allowable infant age at the time of enrollment was dependent on the Dose Group and Cohort:~  * Dose Groups 1, 2, 4 and 5 (Cohort 1): Less than 72 hours of age, and anticipated availability to receive VRC immunization at less than 72 hours after birth.~ * Dose Groups 3, 4 and 5 (Cohort 2): Less than or equal to 5 days of age, and anticipated availability to receive VRC immunization no more than 5 days after birth.~* At increased risk of HIV acquisition defined as documentation of one or more of the following risk factors:~* Dose Groups 1, 2, 4 and 5 (Cohort 1), only:~  * Mother received no antiretroviral therapy (ART) during pregnancy or mother began or reinitiated ART (after an interruption of greater than 14 days), during the third trimester of pregnancy; or~ * Mother with any detectable viral replication (HIV RNA above the limit of detection) at last measurement prior to delivery determined within 30 days of delivery; or~ * Prolonged rupture of membranes (greater than 12 hours); or~ * Mother with documented 2-class resistant HIV infection, which may have included historical documentation of lack of response~    * Women who had a documented history of virologic failure while on non-nucleoside reverse transcriptase inhibitors (NNRTIs) but who had no resistance testing at the time of viral failure were considered to have NNRTI-documented resistance.~* Dose Groups 3, 4 and 5 (Cohort 2), only (African sites):~  * Mother intended to breastfeed~Infant Exclusion Criteria:~* Receipt of any other active or passive HIV immunotherapy or investigational product other than the study vaccine (Note: Infant prophylaxis with any licensed ARV drugs clinically prescribed to prevent mother-to-child HIV transmission were not considered investigational.)~* Receipt of or anticipated need for blood products, immunoglobulin, or immunosuppressive therapy. This included infants who required hepatitis B immunoglobulin (HBIG) but did not require exclusion of infants who received hepatitis B vaccine in the newborn period.~* Documented or suspected serious medical illness, serious congenital anomaly, or immediate life-threatening condition in the infant that may have interfered with the ability to complete study requirements, as judged by the examining clinician~* Any requirement for supplemental oxygen beyond 24 hours of life or requiring supplemental oxygen at the time of the VRC01, VRC01LS, or VRC07-523LS dose~* Baseline laboratory results:~  * Hemoglobin less than 12.0 g/dL~ * Platelet count less than 100,000 cells/mm\^3~ * Absolute neutrophil count: for infants less than or equal to 24 hours old, less than 4,000 cells/mm\^3; for infants greater than 24 hours old, less than 1,250 cells/mm\^3~ * Serum glutamic pyruvic transaminase (SGPT) greater than or equal to 1.25 times upper limit of age adjusted normal~* Dose Groups 1, 2, 4 and 5 (Cohort 1), only: Infant was breastfeeding at time of enrollment or mother had indicated an intention to initiate breastfeeding. Note: if a child was breastfed prior to known maternal diagnosis (in the case of a woman diagnosed in the intrapartum period), the child was still eligible as long as breastfeeding was stopped by the time the child was enrolled and there was no plan to resume breast milk feeding.

- Gender: ALL
- Minimum Age: 0 Days
- Maximum Age: 5 Days
- Healthy Volunteers: f

Study Arms:
- Dose Group 1 (Type: EXPERIMENTAL): Infants in Dose Group 1 received a single VRC01 20 mg/kg injection less than 72 hours after birth.
- Dose Group 2 (Type: EXPERIMENTAL): Infants in Dose Group 2 received a single VRC01 40 mg/kg injection less than 72 hours after birth.
- Dose Group 3 (Type: EXPERIMENTAL): Infants in Dose Group 3 received a VRC01 40 mg/kg injection less than 5 days after birth. They then received a VRC01 20 mg/kg injection monthly for at least 6 months and no more than 18 months while breastfeeding.
- Dose Group 4, Cohort 1 (Type: EXPERIMENTAL): Infants in Cohort 1 received a single VRC01LS injection less than 72 hours after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater.
- Dose Group 4, Cohort 2 (Type: EXPERIMENTAL): Infants in Cohort 2 received an initial VRC01LS injection no longer than 5 days after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater. A second dose of 100 mg VRC01LS was administered at Week 12 if an infant was still breastfeeding.
- Dose Group 5, Cohort 1 (Type: EXPERIMENTAL): Infants in Cohort 1 received a single VRC07-523LS injection less than 72 hours after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater.
- Dose Group 5, Cohort 2 (Type: EXPERIMENTAL): Infants in Cohort 2 received an initial VRC07-523LS injection no longer than 5 days after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater. A second dose of 100 mg VRC07-523LS was administered at Week 12 if an infant was still breastfeeding.

Based on this trial design, predict the completion outcome and termination type (if applicable).